Overcoming Key Hurdles in Decentralized Trials with Better Education

Decentralized clinical trials, and their near cousins that apply a hybrid approach of in-person and remote visits, are increasingly seen as a viable solution for biopharma companies and CROs alike. Recent statements by the FDA and EMA support this emphasis, calling out the need for education and training of all constituents in a clinical trial to reduce unwanted protocol deviations and improve overall quality in clinical trial operations.